Aspen Hunts For Licensing Opportunities After Intense Consolidation
South African Firm ‘Has Scope For Investment’ After Paying Off Debt
Aspen Pharmacare is looking to build and augment where it has laid down foundations, after reshaping its operations with numerous significant divestments.
You may also be interested in...
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
South Africa’s Aspen Pharmacare is continuing along the path of offloading assets that no longer fit into its strategy, using the proceeds to pay off its substantial debt pile and reinvest in areas of greater strategic focus. Half-a-dozen products currently offered in its local market are now on their way to Switzerland’s Acino.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.